H. Lundbeck A/S (HLBBF)
| Market Cap | 6.44B |
| Revenue (ttm) | 3.87B |
| Net Income (ttm) | 501.82M |
| Shares Out | n/a |
| EPS (ttm) | 0.51 |
| PE Ratio | 12.83 |
| Forward PE | 6.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Average Volume | 1,280 |
| Open | 6.90 |
| Previous Close | n/a |
| Day's Range | 6.90 - 6.90 |
| 52-Week Range | 5.10 - 7.55 |
| Beta | 0.22 |
| RSI | 56.02 |
| Earnings Date | May 13, 2026 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Full Company ProfileFinancial Performance
In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.
Financial numbers in DKKNews
H. Lundbeck Transcript: AGM 2026
Record revenues and profitability were achieved in 2025, with strong growth in strategic brands and a robust pipeline. The board and executive team were re-elected, a new member with neuroscience expertise joined, and all proposals—including a 21% dividend increase—were approved.
H. Lundbeck Transcript: Jefferies Global Healthcare Conference
A focused neuroscience strategy, capital reallocation, and a simplified commercial model have driven strong growth, with VYEPTI and REXULTI as key assets. A diversified, innovation-driven pipeline and dynamic investment approach support upgraded financial guidance and long-term ambitions.
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
H. Lundbeck Earnings Call Transcript: Q3 2025
Double-digit revenue and profit growth in the first nine months of 2025 were driven by Vyepti and Rexulti, leading to upgraded full-year guidance. Strategic pipeline advances and commercial restructuring support long-term growth, despite FX and generic headwinds.
H. Lundbeck Earnings Call Transcript: Q2 2025
Strategic brands drove 21% growth and revenue rose 15% year-over-year, prompting upgraded guidance for both revenue and Adjusted EBITDA. Vyepti and Rexulti led performance, while pipeline and capital reallocation support long-term growth.
H. Lundbeck Earnings Call Transcript: Q1 2025
Q1 2025 saw 16% revenue growth and 24% rise in strategic brands, led by Vyepti and Rexulti. Full-year guidance was raised, reflecting strong demand, robust pipeline progress, and disciplined capital allocation, despite anticipated generic competition and portfolio erosion.
H. Lundbeck Transcript: AGM 2025
The AGM highlighted record financial results, a 36% dividend increase, and a strategic focus on rare neurological diseases through acquisitions and pipeline expansion. All board proposals were adopted, and key risks around R&D and market conditions were discussed with shareholders.
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a po...
H. Lundbeck Earnings Call Transcript: Q4 2024
2024 delivered record revenue and double-digit growth in strategic brands, with robust pipeline progress and a major acquisition. 2025 guidance anticipates continued strong growth, margin stability despite higher R&D, and resilience to competitive and generic pressures.
H. Lundbeck Transcript: 43rd Annual J.P. Morgan Healthcare Conference
Significant progress was reported on growth, pipeline transformation, and financial discipline, with four late-stage assets and a robust commercial engine driving mid- and long-term outlook. Major acquisitions and focused R&D investment underpin a news-rich pipeline and sustainable growth strategy.
H. Lundbeck Earnings Call Transcript: Q3 2024
Revenue grew 13% year-over-year, led by 21% growth in strategic brands, with Vyepti and Rexulti as key drivers. The company raised its full-year guidance, reported strong cash flow, and is preparing for the Longboard acquisition, which will shift its net cash to net debt.
H. Lundbeck Transcript: CMD 2024
Focused innovation and capital reallocation are driving double-digit growth in strategic brands and transforming the pipeline, with four phase III programs expected by 2026. Financial guidance is raised, targeting mid-single-digit CAGR and a 30%-32% EBITDA margin, supported by the largest capital allocation program in company history.
H. Lundbeck Transcript: M&A Announcement
The acquisition of Longboard Pharmaceuticals brings a de-risked, late-stage asset with breakthrough therapy designation for rare epilepsies, supporting long-term growth and a focused innovator strategy. The $2.5 billion deal is expected to close by year-end, with peak sales potential of $1.5–2 billion, mainly from the U.S.
H. Lundbeck Earnings Call Transcript: Q2 2024
Double-digit revenue growth and strong strategic brand performance led to raised 2024 guidance. Vyepti, Rexulti, and Brintellix/Trintellix drove results, with robust pipeline progress and a strengthened net cash position.